+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Direct Nose-to-Brain Drug Delivery. Mechanism, Technological Advances, Applications, and Regulatory Updates

  • Book

  • June 2021
  • Elsevier Science and Technology
  • ID: 5238290

Direct Nose-to-Brain Drug Delivery provides the reader with precise knowledge about the strategies and approaches for enhanced nose-to-brain drug delivery. It highlights the development of novel nanocarrier-based drug delivery systems for targeted drug delivery to the brain microenvironments with a focus on the technological advances in the development of the novel drug delivery devices for intranasal administration, including special emphasis on brain targeting through nose. This book explores the various quantification parameters to assess the brain targeting efficiency following intranasal administration and includes an overview on the toxicity aspects of the various materials used to develop the direct nose-to-brain drug delivery vehicles and of the regulatory aspects including patents and current clinical status of the potential neurotherapeutics for the effective management of neuro-ailments. Technological advances in new drug delivery systems with diverse applications in pharmaceutical, biomedical, biomaterials, and biotechnological fields are also explained. This book is a�crucial source that will assist the veteran scientists, industrial technologists, and clinical research professionals to develop new drug delivery systems and novel drug administration devices for the treatment of neuro-ailments.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Section I Basic considerations in nose-to-brain drug delivery

1. An overview of anatomical and physiological aspects of the nose and the brain

Dignesh Khunt and Manju Misra

2. Direct transport theory: From the nose to the brain

Namdev Dhas, Dattatray Yadav, Ashutosh Singh, Atul Garkal, Ritu Kudarha, Priyanka Bangar, Jignasa Savjani, Chandrakantsing V. Pardeshi, Neha Garg, and Tejal Mehta

3. Physicochemical, biopharmaceutical, and practical considerations for efficient nose-to-brain drug delivery

Umesh D. Laddha and Amol A. Tagalpallewar

Section II Nanotechnology and naso-brain drug delivery

4. Nanomedicines for CNS therapy: Fundamental aspects

Drashti Desai, Bala Prabhakar, and Pravin Shende

5. Nanotechnological advances in direct nose-to-brain drug delivery for neurodegenerative disorders and other neuroailments

Rahul Shukla, Ashish Kumar, and S.J.S. Flora

6. Surface modification of nanocarriers as a strategy to enhance the direct nose-to-brain drug delivery

Chandrakantsing V. Pardeshi and Eliana B. Souto

7. Mucoadhesion as a strategy to enhance the direct nose-to-brain drug delivery

Mrunal Patil

8. Nanoparticles for direct nose-to-brain drug delivery: Implications of targeting approaches

Raju O. Sonawane, Yogeshwar Bachhav, Avinash R. Tekade, and Chandrakantsing V. Pardeshi

9. Strategies for enhanced direct nose-to-brain drug delivery

Yamini Madav and Sarika Wairkar

Section III Carriers for direct nose-to-brain drug delivery

10. Particulate carriers for nose-to-brain delivery

Shiv Bahadur and Kamla Pathak

11. Vesicular carriers for direct nose-to-brain drug delivery

Prashant K. Deshmukh, Swapnil N. Jain, Pravin O. Patil, and Chandrakantsing V. Pardeshi

12. Gel-based delivery of neurotherapeutics via naso-brain pathways

Hitendra S. Mahajan and Payal H. Patil

Section IV Applications of direct nose-to-brain delivery

13. Applications of direct nose-to-brain drug delivery in medicine and pharmacy

Ganesh B. Shevalkar, Mahendra K. Prajapati, Rohan V. Pai, and Kamlesh D. Mali

14. Applications of direct nose-to-brain drug delivery in biomedicine, biotechnology, tissue engineering, and immunology

Sanjay B. Patil

15. Diagnostic and theranostic intranasal nanointerventions for brain diseases

Prashant Upadhaya, Sreeranjini Pulakkat, and Vandana Patravale

16. Nose-to-brain delivery of biologics and stem cells

Mukta Agrawal, Aditya Narayan Konwar, Amit Alexander, and Vivek Borse

17. Applications of nose-to-brain delivery in nanodiagnosis and nanotherapy of neurodegenerative disorders

Abhijeet Kulkarni, Mahesh Shinde, Gaurav Sonawane, Hitesh Raotole, Rohit Pande, and Chandrakantsing V. Pardeshi

18. Intranasal gene therapy for the treatment of neurological disorders

Namdev Dhas, Tejal Mehta, Shilpa Sharma, Atul Garkal, Dattatray Yadav, Kartik Hariharan, Babeeta Shamjetshabam, Shubham Khot, Ritu Kudarha, Priyanka Bangar, Gajanan Arbade, and Pratap Kalyankar

19. Potential of naso-brain drug delivery in glioblastoma therapy

Amarjitsing Rajput, Nikunj Tandel, Swapnil Borse, and Shital Butani

20. Nose-to-brain delivery of antiretroviral drugs against NeuroAIDS

Kailas K. Moravkar, Devanshi S. Shah, Durgesh K. Jha, Purnima D. Amin, and Sanjay J. Surana

Section V Technological advances for effective drug administration

21. A technology overview on advanced drug administration devices for effective nose-to-brain delivery

Sadhana R. Shahi and Chandrakantsing V. Pardeshi

Section VI Evaluation of direct nose-to-brain drug delivery

22. Experimental models for evaluation of direct nose-to-brain drug delivery

Vinit V. Agnihotri, Ashish P. Gorle, Chandrakantsing V. Pardeshi, and Sanjay J. Surana

23. Quantitative and qualitative analysis of direct nose-to-brain drug delivery

Veena S. Belgamwar, Vidyadevi T. Bhoyar, Sagar Trivedi, and Chandrakantsing V. Pardeshi

Section VII Toxicity and regulatory aspects

24. Toxicity aspects: Crucial obstacles to clinical translation of nanomedicines

Vikas Bansal, Sameer S. Katiyar, and Chander Parkash Dora

25. Nose-to-brain drug delivery: Regulatory aspects, clinical trials, patents, and future perspectives

Abhijeet Pandey, Ajinkya Nikam, Shreya Basavraj, Sadhana Mutalik, Divya Gopalan, Sanjay Kulkarni, Bharat Padya, Gasper Fernandes, and Srinivas Mutalik

Authors

Chandrakantsing Pardeshi Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon, India. Dr. Chandrakantsing Pardeshi holds PhD degree in Pharmaceutical Sciences from Kavayitri Bahinabai Chaudhari North Maharashtra University (KBC NMU, India). Presently, he is an Associate Professor of Pharmaceutics at R. C. Patel Institute of Pharmaceutical Education and Research (Shirpur, India) where he is inventing the novel devices for direct nose-to-brain drug delivery. Dr. Pardeshi has authored more than 50 peer-reviewed publications, 21 book chapters and several research abstracts. He has, to his credit, 2 Indian patents and 1 research project funded by University Grants Commission (New Delhi, India). He is an active referee and editorial board member of few reputed multidisciplinary international journals. Dr. Pardeshi also contributed as a Grant evaluator in Government Funding bodies. He has been awarded with Gold Medal from KBC NMU (India), and Excellence Award from Indian Drug Manufacturer's Association (IDMA, India). Eliana B. Souto Professor, Department of Pharmaceutical Technology of the Faculty of Pharmacy, University of Porto, Portugal. Eliana B. Souto is Habil. Professor from the Department of Pharmaceutical Technology of the Faculty of Pharmacy of University of Porto. Prof. Souto graduated in Pharmaceutical Sciences from University of Coimbra (2000), is holder of a master's in science degree in Pharmaceutical Technology from University of Porto (2002), and PhD in Pharmaceutical Nanotechnology and Biopharmaceutics from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Her research lines include the design, development, and characterization of new drug delivery systems to overcome biological barriers. Prof. Souto serves as Associate Editor, member of the Editorial Board, and Reviewer of several international scientific journals and has published more than 500 works (original and review papers, books and book chapters) in the field of nanosciences and nanomedicine. Prof. Souto also acts as independent expert for several national, European and international funding agencies, and as consultant for pharmaceutical industry.